Search | CATIE - Canada's source for HIV and hepatitis C information

Jump to Navigation Jump to Content

Sort Results

Filter by Specific Population

Older adults (1)

Filter by Topic

Treatment (remove)
- HIV drugs (remove)
  - Tenofovir (viread) (remove)
  - Genvoya (3)
  - Atazanavir (Reyataz) (2)
  - Kaletra (lopinavir/ritonavir) (2)
  - Dolutegravir (Tivicay) (1)
  - Ritonavir (Norvir) (1)
- Side effects (11)
Organ and body health (8)
Infections and cancers (1)

Filter by Infection

HIV (remove)

Filter by Resource Category

Search results

Current filters: HIV, Treatment, HIV drugs, Tenofovir (viread)

13 search results

1
2

Dolutegravir and TAF or TDF—safety issues and weight gain: From TreatmentUpdate 235
2020, CATIE
Research summary - Webpage
Does tenofovir (TDF) cause liver injury?: 2016, CATIE
Research summary - Webpage
A study about switching from TDF to TAF: From TreatmentUpdate 211
2015, CATIE
Research summary - Webpage
TAF vs. TDF (original tenofovir)—improvements in safety: From TreatmentUpdate 211
2015, CATIE
Research summary - Webpage
TAF is coming: From TreatmentUpdate 211
2015, CATIE
Research summary - Webpage
Putting reports of kidney injury into perspective: From TreatmentUpdate 195
2013, CATIE
Research summary - Webpage
Kidney injury and anti-HIV drugs – the latest from the DAD study: From TreatmentUpdate 195
2013, CATIE
Research summary - Webpage
Risk factors for kidney dysfunction: From TreatmentUpdate 195
2013, CATIE
Research summary - Webpage
Tenofovir and telomeres – is there a link?: From TreatmentUpdate 195
2013, CATIE
Research summary - Webpage
Changes in bone density among HIV-negative men, some of whom used tenofovir: From TreatmentUpdate 189
2012, CATIE
Research summary - Webpage

1
2

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.

We comply with the HONcode standard for trustworthy health information: verify here.

Please note that some content on this website contains language, information and images related to sexuality and drug use, and may not be intended for people of all ages. CATIE ensures that these resources, developed to help prevent the transmission of HIV, hepatitis C and other infections, are written and reviewed by health experts for content accuracy.